-
MEDICATIONS
- ANALGESICS
- ALLERGY
- ANTIFUNGAL
- ANTIMICROBIAL
- ANTIPARASITICS
- ANTISEPTICS
- BONES AND JOINTS
- COUGH AND ANTIVIRAL
- DERMATOLOGY
- CARDIOLOGY
- GENITOURINARY SYSTEM
- GYNECOLOGY
- HOMEOPATHY
- HAEMORRHOIDS
- ONCOLOGY
- INCREASE POTENCY
- RESPIRATORY SYSTEM
- HORMONES
- IMMUNE SYSTEM
- NEUROLOGY
- ANXIETY AND INSOMNIA
- OPHTHALMOLOGY
- OTHER
- STOMACH. INTESTINES. LIVER
- TOPICAL MEDICATIONS
- WEIGHT LOSS. METABOLIC DISORDERS
-
SUPPLEMENTS
- ANTIOXIDANT COMPLEXES
- BEER YEAST
- CALCIUM, D3, FISH OIL
- EYE VITAMINS
- HERBALS
- IRON PREPARATIONS
- MACRO AND TRACE ELEMENTS
- MONO-AND MULTIVITAMINS
- RESTORATIVE
- SUPPLEMENTS FOR THE DIGESTIVE TRACT, LIVER, KIDNEYS
- TONIC
- VITAMIN AND MINERAL COMPLEXES
- VITAMIN C
- VITAMIN D
- VITAMIN E
- VITAMINS FOR CHILDREN
- VITAMINS FOR MEN
- VITAMINS FOR PREGNANT AND LACTATING
- VITAMINS FOR SKIN, HAIR, NAILS
- VITAMINS FOR WOMEN
- VITAMINS PREMIUM CLASS SOLGAR (SOLGAR)
-
MEDICAL SUPPLIES
-
BEAUTY
-
COSMETIC BRANDS
- BEAUTY CARE (BISI)
- BIODERMA
- BIORGA
- CERAVE (CERAW)
- ZINOVIT
- DNC (DNC COSMETICS)
- DRY DRY (DRY DRY)
- DUCRAY (DUCRE)
- ELANCYL (ELANSIL)
- ELFAPHARM (ELFA PHARM)
- EVA (EVA)
- FILORGA (FILORGA)
- FITO COSMETICS (PHYTO COSMETIC)
- FLORESAN
- HORMETA (ORMETA)
- INSTITUT ESTHEDERM (ESTEDERM)
- IQ BEAUTY (IQ BEAUTY)
- KLORANE (CLORAN)
- KNEIPP (KNIPP)
- KORFF (KORFF)
- LA ROCHE-POSAY (LA ROSH POSE)
- LAINO (LENO)
- LIBREDERM (LIBRIDERM)
- LIERAC
- FILLERS
-
COSMETIC BRANDS
VINPOCETINE FORTE PILLS 10MG
VINPOCETINE FORTE PILLS 10MG - 30 tabs
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Composition
1 pill contains the active substance: Vinpocetine - 10.0 mg
Pharmacotherapeutic group
Cerebral blood flow improving agent
pharmachologic effect
It improves brain metabolism by increasing the consumption of glucose and oxygen by the brain tissue. Increases the resistance of neurons to hypoxia; enhancing glucose transport to the brain, through the blood-brain barrier; translates the process of the breakdown of glucose to an energetically more economical, aerobic way.
Increases ATP concentration and ATP / AMP ratio in brain tissues; enhances the metabolism of norepinephrine and brain serotonin; has an antioxidant effect. Vinpocetine selectively inhibits voltage-dependent sodium channels, causing a dose-dependent decrease in the concentration of Calcium ions in the endings of the striatal neurons. It is believed that reducing the current of sodium ions has a neuroprotective effect due to a decrease in excitotoxicity and the weakening of neuronal damage caused by cerebral ischemia and reperfusion. Vinpocetine increases the concentration of 3,4-dihydroxyphenylacetic acid (dopamine metabolite) in the nerve endings of the striatum. It also inhibits phosphodiesterase-1, which leads to an increase in the concentration of intracellular cyclic guanosine monophosphate.Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by erythrocytes; contributes to increased oxygen return by red blood cells. Enhances the neuroprotective effect of adenosine. Increases cerebral blood flow; reduces the resistance of cerebral vessels without significant changes in the systemic blood circulation (blood pressure, minute volume, heart rate, general peripheral resistance). Not only does not have the effect of “stealing”, but also enhances the blood supply, primarily in ischemic brain regions with low perfusion.
Indications for use
Hypersensitivity to vinpocetine and other components of the drug. Acute phase of hemorrhagic stroke, severe coronary heart disease, severe arrhythmias.
Pregnancy and lactation. Children under 18 years (due to lack of data). lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
Contraindications
Hypersensitivity to any of the components that make up the drug, pregnancy and lactation, age up to 12 years, lactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.
Dosage and administration
The course of treatment and dosage is determined by the attending physician. Inside, after eating. The standard daily dose of 5-10 mg 3 times a day. The maximum daily dose of 30 mg.The therapeutic effect develops approximately in a week from the beginning of the drug intake. The course of treatment is 1-3 months. For diseases of the kidneys and liver, the drug is prescribed in the usual dose, the lack of cumulation allows for long-term courses of treatment.
Release form
30 pills per pack
Pharmacy sales terms
On prescription.